Literature DB >> 25304369

The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells.

Wei Jia1, Sterling K Tran1, Caitlin A Ruddick1, Mandi M Murph2.   

Abstract

The LPA3 receptor is a G protein-coupled receptor that binds extracellular lysophosphatidic acid and mediates intracellular signaling cascades. Although we previously reported that receptor inhibition using siRNA or chemical inhibition obliterates the viability of melanoma cells, the mechanism was unclear. Herein we hypothesized that amino acids comprising the Src homology 3 (SH3) ligand binding motif, R/K-X-X-V/P-X-X-P or (216)-KTNVLSP-(222), within the third intracellular loop of LPA3 were critical in mediating this outcome. Therefore, we performed site-directed mutagenesis of the lysine, valine and proline, replacing these amino acids with alanines, and evaluated the changes in viability, proliferation, ERK1/2 signaling and calcium in response to lysophosphatidic acid. Our results show that enforced LPA3 expression in SK-MEL-2 cells enhanced their resiliency by allowing these cells to oppose any loss of viability during growth in serum-free medium for up to 96 h, in contrast to parental SK-MEL-2 cells, which show a significant decline in viability. Similarly, site-directed alanine substitutions of valine and proline, V219A/P222A or 2aa-SK-MEL-2 cells, did not significantly alter viability, but adding a further alanine to replace the lysine, K216A/V219A/P222A or 3aa-SK-MEL-2 cells, obliterated this function. In addition, an inhibitor of the LPA3 receptor had no impact on the parental SK-MEL-2, 2aa-SK-MEL-2 or 3aa-SK-MEL-2 cells, but significantly reduced viability among wt-LPA3-SK-MEL-2 cells. Taken together, the data suggest that the SH3 ligand binding domain of LPA3 is required to mediate viability in melanoma cells.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  LPA(3); Lysophosphatidic acid; SH3 domain

Mesh:

Substances:

Year:  2014        PMID: 25304369     DOI: 10.1016/j.canlet.2014.10.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

Review 1.  Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Gabor J Tigyi; Junming Yue; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Louisa Balazs; Guannan Zhao; Sue Chin Lee
Journal:  Adv Biol Regul       Date:  2018-09-16

2.  Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA1, LPA2, and LPA3.

Authors:  Rocío Alcántara-Hernández; Aurelio Hernández-Méndez; Gisselle A Campos-Martínez; Aldo Meizoso-Huesca; J Adolfo García-Sáinz
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

3.  Paradoxical downregulation of LPAR3 exerts tumor-promoting activity through autophagy induction in Ras-transformed cells.

Authors:  Sung-Hee Hwang; Hye-Gyo Kim; Michael Lee
Journal:  BMC Cancer       Date:  2022-09-10       Impact factor: 4.638

Review 4.  MicroRNA Regulation of the Autotaxin-Lysophosphatidic Acid Signaling Axis.

Authors:  Mandi M Murph
Journal:  Cancers (Basel)       Date:  2019-09-14       Impact factor: 6.639

Review 5.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

Review 6.  Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.

Authors:  Yu-Hsuan Lin; Yueh-Chien Lin; Chien-Chin Chen
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.